Previous Close | 31.31 |
Open | 31.53 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 31.53 - 31.88 |
52 Week Range | 31.13 - 40.48 |
Volume | |
Avg. Volume | 1,812,180 |
Market Cap | 205.192B |
Beta (5Y Monthly) | 0.15 |
PE Ratio (TTM) | 16.02 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.39 (4.45%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RHHBY
The company is pitching the test as a way to improve the safety and availability of blood.
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.